The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were […]readmore
Tags : Abbott
1. Johnson & Johnson Initiates Voluntarily Recall of a Single Lot of its Baby Powder in the US Published: Oct 18, 2019 | Tags: JnJ, Initiates, Voluntarily, Recall, Baby Powder, US […]readmore
Shots: The companies collaborated to develop & commercialize integrated diabetes solutions combining Abbott’s FreeStyle Libre System with the Tandem’s t:slim X2 insulin pump expanding choice for the patients to manage […]readmore
Shots: The collaboration integrates Abbott’s FreeStyle Libre system, a CGM technology, with Omada Health’s digital care program focusing to create a new paradigm for patients with T2D The integrated solution […]readmore
The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer’s […]readmore
1. Incyte Reports Updated Results of Pemigatinib in P-II FIGHT-202 Trial for Patients with Previously Treated Advanced Cholangiocarcinoma Published: Sept 27, 2019 | Tags: Incyte, Reports, Updated, Results, Pemigatinib, P-II, FIGHT-202 […]readmore
Shots: Abbott’s High Sensitivity Troponin-I blood test measures very low levels of troponin, allowing doctors to evaluate heart attack in patients within 2-4 hrs. of admission as the elevated level […]readmore
1.Boehringer Ingelheim Enters into an Agreement with Inflammasome Therapeutics to Co-Develop Therapies for Retinal Diseases Published: Sept 20, 2019 | Tags: Boehringer Ingelheim, Agreement, Inflammasome Therapeutics, Co-Develop, Therapies, Retinal Disease 2. […]readmore
Shots: Abbott and Sanofi team up to develop tools integrating their blood sugar tracking and insulin delivery technologies to help diabetes patients in managing their conditions The non-exclusive agreement will […]readmore
1. Eisai And Biogen to Terminate Two P-III Clinical Studies of Elenbecestat (E2609) for Early Alzheimer’s Disease Published: Sept 13, 2019 | Tags: Eisai, Biogen, Terminate Two, P-III, Clinical Studies, Elenbecestat, […]readmore